GlassScriptPhysician profile
Gabriel Marrero
NPI 1871789214
$8,790.58
in general payments reported to CMS, 2019-2025
32 companies · $364 in 2025
The $364 reported for 2025 was less than what a typical Pain Medicine (Physical Medicine & Rehabilitation) provider received nationally (typical 2025 total: $400).
See the full distribution for Pain Medicine (Physical Medicine & Rehabilitation)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,760 · 2020: $520 · 2021: $908 · 2022: $1,390 · 2023: $2,102 · 2024: $747 · 2025: $364.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,278 · Travel and Lodging: $934.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,278.14 |
| Travel and Lodging | $934.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nalu Medical, INC. | $2,818.87 | 2021-2023 | Nalu Neurostimulation System |
| Vertiflex, INC. | $1,622.90 | 2019 | |
| Medtronic, INC. | $992.37 | 2021-2025 | Intellis Adaptivestim, Accurian |
| Boston Scientific Corporation | $679.88 | 2019-2025 | General - Pain Management, Intracept |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $354.81 | 2019-2023 | Relistor |
| Collegium Pharmaceutical, INC. | $298.97 | 2019-2024 | Belbuca, Xtampza |
| Curonix LLC | $285.01 | 2024-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Abbott Laboratories | $268.20 | 2019-2020 | |
| Spr Therapeutics, INC | $168.54 | 2022-2023 | Sprint Pns System |
| Scilex Pharmaceuticals INC. | $158.98 | 2019-2022 | |
| Stryker Corporation | $150.00 | 2024 | Mild Device Kit |
| Biodelivery Sciences International, INC. | $142.43 | 2019-2020 | |
| Medtronic USA, INC. | $118.64 | 2019 | |
| Nevro Corp. | $114.26 | 2020 | |
| Vertos Medical, INC. | $104.18 | 2019-2024 | Mild Device Kit |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $87.81 | 2021 | |
| Forte Bio-Pharma LLC | $45.17 | 2021 | |
| Tersera Therapeutics LLC | $45.06 | 2019 | |
| Azurity Pharmaceuticals, INC. | $36.77 | 2023 | Horizant |
| Zyla Life Sciences, INC. | $36.09 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $34.15 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $32.76 | 2025 | |
| Kaleo, INC. | $24.76 | 2019 | |
| Daiichi Sankyo INC. | $23.08 | 2019 | |
| Depuy Synthes Sales INC. | $21.40 | 2019 | |
| Spinal Simplicity, LLC | $21.29 | 2025 | Ha Minuteman G3-R |
| Amgen INC. | $20.99 | 2021 | |
| Foundation Fusion Solutions, LLC | $18.79 | 2023-2024 | |
| Mdd US Operations, LLC | $17.46 | 2020 | |
| Pfizer INC. | $16.12 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $16.03 | 2022 | |
| Valinor Pharma, LLC | $14.81 | 2025 | Movantik |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gabriel Marrero listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.